Building a CAR-T CMC Strategy on a Limited Budget

Early developers do not need a finalized commercial process before first-in-human studies, but they do need a clear plan for managing cost, scalability, comparability, and future manufacturing changes

By
Kate Fynes
October 6, 2026
8 min

The Medicine Maker

At a Glance

Category	Detail
Condition	CAR-T Cell Therapy Development
Key Mechanisms	Chemistry, Manufacturing, and Controls (CMC) strategy focused on speed and risk assessment.
Target Population	Early developers of CAR-T therapies.
Care Setting	Clinical development and regulatory environments.

Key Highlights

A phase-appropriate CMC strategy is essential for early CAR-T developers.
Cost-of-goods modeling should be initiated early to identify potential long-term viability issues.
Sensitivity analysis helps prioritize process improvements based on economic impact.
Documentation of decisions and risks is crucial for regulatory and investor alignment.
Transitioning from manual to automated processes is necessary for scalability.

Guideline-Based Recommendations

Diagnosis

Management

Establish a staged CMC development pathway connecting current processes to future goals.
Use GMP-suitable materials where possible and justify alternatives.

Monitoring & Follow-up

Implement controlled documentation and appropriate reviews throughout the development process.

Risks

Changes made after FIH may trigger comparability expectations and require additional analytical work.

Patient & Prescribing Data

Not specified; focuses on developers rather than patients.

Early-stage developers should prioritize decisions that support immediate progress while planning for later development.

Clinical Best Practices

Develop a clear, data-driven cost-of-goods model early in the process.
Utilize sensitivity analysis to guide resource allocation and process improvement decisions.
Maintain a living document that evolves with the program to track milestones and changes.